Denali reports first full AVLAYAH quarter, advances Alzheimer's pipeline, sells PRV for $195 million
Denali posted $3.6 million in net AVLAYAH revenue for Q2 2026, guided to $10-12 million for Q3, and disclosed a delayed DNL593 readout and a discontinued Parkinson's program.
SEC filing